Citi Pharma Limited

Care to Cure

October 28, 2022

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

Financial results for the 1st quarter ended September 30, 2022

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on October 28, 2022 at Lahore have approved the financial statements for the 1st Quarter ended on September 30, 2022 and recommended the following.

Cash Dividend	Nil
Bonus Shares	Nil
Right Shares	Nil
Any other entitlement/corporate action	Nil
Any other Price sensitive information	Nil

Financial Performance:

While reviewing the Company financial performance for the quarter ended, the Board appreciated the efforts of the management in the area of operation and posting the financial results.

In the period under review net sales of the company has improved to Rs. 3,118 million as compared to Rs. 1,990 million in the corresponding period of the last period and registered a growth of 57%. Similarly, the Gross Profits has improved to Rs. 370 million as compared to last quarter ended September 30, 2021 of Rs. 296 million. Net profit of the company has improved to Rs. 145 million as compared to last quarter ended September 30, 2021 of Rs. 81 million, an increase of almost 79% in spite of exchange loss of Rs 130 million due to continued devaluation of the Pak Rupee.

The Earning per share of the company also improved from Rs. 0.37 per share to Rs. 0.64 per share almost an increase of 72% from last period.

Financial results of the company for the first quarter ended September 30, 2022 are enclosed.

Quarterly report of the Company for the quarter ended September 30, 2022 will be transmitted through PUCARS separately, within the specified time.

Yours Sincerely,

CITI PHARMA LIMITED

Muhammad Riaz
Company Secretary

Cc:
Executive Director/HOD, Offsite-II, Department
Supervision Division, Securities & Exchange Commission of Pakistan

Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE PERIOD ENDED SEPTEMBER 30, 2022

	Quarter Ended	
	September 30, 2022 (Un-audited)	September 30, 2021 (Un-audited)
Sales- Net	3,118,074,356	1,990,952,817
Cost of sales	(2,747,684,203)	(1,694,611,260)
Gross profit	370,390,153	296,341,557
Administrative expenses	49,715,005	159,888,341
Selling and Distribution expenses	37,663,377	25,419,521
	(87,378,383)	(185,307,862)
Operating Profit	283,011,771	111,033,695
Financial Charges	(157,053,888)	(8,201,778)
	125,957,882	102,831,917
Other income/(Loss)	47,598,134	30,852,125
	173,556,016	133,684,042
Other Expenses	(4,219,670)	(8,764,202)
Profit before Taxation	169,336,346	124,919,840
Taxation	(23,527,710)	(43,563,166)
Profit for the period	145,808,636	81,356,674
Earnings per share (EPS)		Restated
- Basic and Diluted	0.64	0.37

CITI PHARMA LIMITED

588 - Q, Johar Town, Lahore - Pakisatn
3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan
Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392 www.citipharma.com.pk